About Spectracef

SPECTRACEF is an effective antibiotic therapy for patients.

  • Provides convenience and promotes compliance
  • Treatment against sensitive bacteria
  • Delivers the effective empiric therapy of a third-generation cephalosporin

What is SPECTRACEF?

SPECTRACEF tablets are indicated to treat mild to moderate bacterial infections in patients 12 years of age or older. It works by stopping the growth of sensitive bacteria and tablets contain Cefditoren Pivoxil, a semi-synthetic cephalosporin antibiotic for oral administration. It is a prodrug, which is hydrolyzed by esterases during absorption, and the medicine is distributed in the circulating blood as active cefditoren.

What does SPECTRACEF treat?

SPECTRACEF is a highly effective treatment for community-acquired pneumonia (CAP), a proven treatment for acute bacterial exacerbation of chronic bronchitis (ABECB) and a dependable therapy for streptococcal pharyngitis.

SPECTRACEF treats only bacterial infections. It will not work for viral infections (e.g., common cold, flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

More about SPECTRACEF

SPECTRACEF is manufactured by Cornerstone Therapeutics Inc.

Cornerstone Therapeutics

Cornerstone Therapeutics Inc. (Nasdaq: CRTX), headquartered in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory market. The Company currently promotes multiple marketed products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. The Company also has a late-stage clinical pipeline with five regulatory approval submissions targeted within the next three years. Key elements of the Company's strategy are to in-license or acquire rights to underpromoted, patent-protected, branded respiratory pharmaceutical products, or late-stage product candidates; implement life cycle management strategies to maximize the potential value and competitive position of the Company's currently marketed products, newly acquired products and product candidates that are currently in development; grow product revenue through the Company's specialty sales force which is focused on the respiratory market; and maintain and strengthen the intellectual property position of the Company's currently marketed products, newly acquired products and product candidates. For more information, visit www.crtx.com.

Co-pay assistance program makes SPECTRACEF affordable.

For full Prescribing Information, click here.



References

1. SPECTRACEF® (cefditoren pivoxil) prescribing information, Cornerstone Therapeutics Inc., September 2009.

About Us